Mode
Text Size
Log in / Sign up

Biologics provide effective and long-lasting disease control for chronic rhinosinusitis with nasal polypsBiologics May Help Chronic Sinusitis With Nasal Polyps

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider biologics for CRSwNP to improve symptoms, reduce polyp volume, and decrease corticosteroid use.

This narrative review synthesizes the clinical evidence regarding the use of biologics, specifically dupilumab, mepolizumab, omalizumab, and tezepelumab, in the management of chronic rhinosinusitis with nasal polyps (CRSwNP). The review focuses on the impact of these agents on disease control, anatomical changes, and patient-reported outcomes.

The authors conclude that these biologics provide effective and long-lasting disease control. Specifically, the review notes that these treatments lead to reduced polyp volume, improved nasal symptoms, and improved olfactory function. Furthermore, the use of these biologics is associated with a decreased reliance on oral corticosteroids and a decreased need for reoperation.

A primary limitation of this evidence is the narrative nature of the review, which does not provide primary trial data or specific effect sizes. Clinical application is supported by the ability of biologics to allow for individualized decision-making based on specific patient endotypes, comorbidities, and treatment goals. The findings suggest these agents are viable options for managing CRSwNP, though specific magnitude of effect is not reported.

How this fits prior evidence

This narrative review addresses a gap in the management of chronic rhinosinusitis with nasal polyps by evaluating specific biologics. It extends the clinical utility of dupilumab, which was previously noted to show moderate-to-high certainty benefit for dysphagia in eosinophilic esophagitis. While the review does not provide specific trial data, it confirms the role of biologics in managing airway inflammatory conditions.

A new narrative review looked at how well biologic drugs work for people with chronic rhinosinusitis with nasal polyps. The review focused on four biologics: dupilumab, mepolizumab, omalizumab, and tezepelumab. It did not include new patient data or specific numbers, but it summarized findings from existing clinical evidence.

The review reports that these biologics were linked to better disease control that lasted a long time. They also appeared to reduce polyp size, improve nasal symptoms, and improve the sense of smell. People using biologics may rely less on oral corticosteroids and may need fewer repeat surgeries. The review also notes possible benefits for asthma that often occurs alongside nasal polyps.

However, this is a narrative review, not a primary study. It does not provide details on side effects, serious adverse events, or how many people stopped treatment. The review also does not give effect sizes or certainty of the evidence. That means we cannot say how large these benefits are or how they compare to other treatments.

What readers can take away: biologics are a promising option for some people with nasal polyps, especially when other treatments have not worked. But decisions about biologics should be made with a doctor, based on individual factors like endotype, other conditions, and treatment goals.

What this means for you:
Biologics may improve sinus symptoms and smell in nasal polyps, but more details on safety and size of benefit are needed.

Common questions

What are biologics for nasal polyps?

Biologics are drugs made from living cells that target specific parts of the immune system. The review looked at four: dupilumab, mepolizumab, omalizumab, and tezepelumab. They are given by injection and are usually considered when other treatments do not control symptoms well. The review suggests they may help with polyps, nasal symptoms, and asthma.

Do biologics help with smell loss from nasal polyps?

The review reports that olfactory function, or the sense of smell, improved in people using these biologics. However, the review does not give specific numbers or effect sizes, so it is not clear how much improvement people might expect. Talk to your doctor about whether a biologic might help your smell loss.

Can biologics reduce the need for surgery or steroids?

The review found that reliance on oral corticosteroids decreased and the need for reoperation decreased in people using biologics. This suggests biologics might help some people avoid repeated steroid courses or additional surgeries. But the review does not provide details on how many people benefited or how long the effect lasted.

What are the side effects of biologics for nasal polyps?

The review does not report any information on side effects, serious adverse events, or how many people stopped treatment. That is a key limitation. Before starting a biologic, ask your doctor about the known risks and whether it is safe for your specific situation.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
BackgroundChronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic airway disease characterized mainly by type 2 inflammation, which seriously impairs patients' quality of life and imposes a huge economic burden. Traditional treatments cannot eradicate underlying immune disorders, leading to high postoperative recurrence. This review aims to summarize the pathophysiological basis of CRSwNP and the clinical application advances of biologics in its precision treatment.MethodsA narrative review was performed to synthesize key literature on the pathophysiology of CRSwNP, focusing on the core role of type 2 inflammatory molecules (IL-4, IL-13, IL-5, IgE, TSLP) and the clinical evidence of targeted biologics for refractory CRSwNP.ResultsIn-depth understanding of CRSwNP pathophysiology has promoted the shift to precision medicine. Biologics including dupilumab (anti-IL-4Rα), mepolizumab (anti-IL-5), omalizumab (anti-IgE) and tezepelumab (anti-TSLP) can precisely target key molecules in type 2 inflammatory pathways, achieving effective and long-lasting disease control, reducing polyp volume, improving nasal symptoms and olfactory function, decreasing reliance on oral corticosteroids and the need for reoperation, and exerting synergistic effects on comorbid asthma.ConclusionsBiologics mark a milestone in CRSwNP treatment, shifting clinical management from symptomatic treatment to individualized decision-making based on patient endotypes, comorbidities and treatment goals such as disease remission. Future research will focus on predictive biomarkers, head-to-head comparative studies and new targets for non-type 2 inflammation to optimize long-term management. By integrating recent biologic evidence with endotype-based recurrence mechanisms, this review provides a practical framework for biologic stewardship and remission-oriented management in CRSwNP.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.